2 Reasons to Like HALO (and 1 Not So Much) [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
The stock also fell short of the S&P 500's 6.2% gain during that period. Is now the time to buy HALO? Or does the price properly account for its business quality and fundamentals? Find out in our full research report, it's free Why Does HALO Stock Spark Debate? Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ:HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration. Two Things to Like: 1. Skyrocketing Revenue Shows Strong Momentum Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Halozyme Therapeutics's sales grew at an incredible 39.2% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics (HALO) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "buy (b-)" to "hold (c)".MarketBeat
- Halozyme to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Halozyme to Participate in Upcoming Investor ConferencesPR Newswire
- Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- HALO's page on the SEC website